Moleculin Biotech (NASDAQ:MBRX – Get Free Report) and Biora Therapeutics (NASDAQ:BIOR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.
Profitability
This table compares Moleculin Biotech and Biora Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moleculin Biotech | N/A | -157.44% | -97.16% |
| Biora Therapeutics | N/A | N/A | -332.47% |
Analyst Recommendations
This is a summary of current ratings and target prices for Moleculin Biotech and Biora Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moleculin Biotech | 0 | 0 | 2 | 0 | 3.00 |
| Biora Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Insider and Institutional Ownership
15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are owned by institutional investors. 7.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 51.1% of Biora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Moleculin Biotech has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, indicating that its stock price is 12% more volatile than the S&P 500.
Earnings and Valuation
This table compares Moleculin Biotech and Biora Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moleculin Biotech | N/A | N/A | -$29.77 million | N/A | N/A |
| Biora Therapeutics | $892,000.00 | 0.63 | -$124.11 million | ($13.04) | -0.01 |
Moleculin Biotech has higher earnings, but lower revenue than Biora Therapeutics.
Summary
Biora Therapeutics beats Moleculin Biotech on 5 of the 9 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
About Biora Therapeutics
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
